Article
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 1 Nov 2006
Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour D C, Malaise J, Lison D, Mourad M
Abstract excerpt
Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G > A, CYP3A5*3; 14690A > G, CYP3A5*6) and drug transporter ABCB1 (1236C > T; 2677G > T/A; 3435C > T) are known to influence tacrolimus (Tac) dose requirements and trough blood levels in stable transplant patients. In a group of 19 volunteers selected with relevant genotypes among a list of 221 adult renal transplant candidates, we evaluated whether...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
